nach oben

Erschienen in:

01.03.2011 | Original

Cost-effectiveness of the Surviving Sepsis Campaign protocol for severe sepsis: a prospective nation-wide study in Spain

verfasst von: David Suarez, Ricard Ferrer, Antonio Artigas, Izaskun Azkarate, José Garnacho-Montero, Gemma Gomà, Mitchell M. Levy, Juan Carlos Ruiz, For the Edusepsis Study Group

Erschienen in: Intensive Care Medicine | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Context

Severe sepsis is associated with high mortality and increased costs. The ‘Surviving Sepsis Campaign’ (SSC) protocol was developed as an international initiative to reduce mortality. However, its cost-effectiveness is unknown.

Objective

To determine the cost-effectiveness of the SSC protocol for the treatment of severe sepsis in Spain after the implementation of an educational program compared with the conventional care of severe sepsis.

Design

Observational prospective before-and-after study.

Setting

59 medical-surgical intensive care units located throughout Spain.

Patients

A total of 854 patients were enrolled in the pre-educational program cohort (usual or standard care of severe sepsis) and 1,465 patients in the post-educational program cohort (SSC protocol care of severe sepsis).

Interventions

The educational program aimed to increase adherence to the SSC protocol. The SSC protocol included pharmacological and medical interventions.

Main outcome measures

Clinical (hospital mortality) and economic (health-care resource and treatment costs) outcomes were recorded. A health-care system perspective was used for costs. The primary outcome was incremental cost-effectiveness ratio (ICER).

Results

Patients in the SSC protocol care cohort had a lower risk of hospital mortality (44.0% vs. 39.7%, P = 0.04). However, mean costs per patient were 1,736 euros higher in the SSC protocol care cohort (95% CI 114–3,358 euros), largely as a result of increased length of stay. Mean life years gained (LYG) were higher in the SSC protocol care cohort: 0.54 years (95% CI 0.02–1.05 years). The adjusted ICER of the SSC protocol was 4,435 euros per LYG. Nearly all (96.5%) the bootstrap replications were below the threshold of 30,000 euros per LYG.

Conclusion

The SSC protocol seems to be a cost-effective option for treating severe sepsis in Spain.

Nur mit Berechtigung zugänglich

Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546–1554CrossRefPubMed

Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B (1995) Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 274:968–974CrossRefPubMed

Guidet B, Aegerter P, Gauzit R, Meshaka P, Dreyfuss D (2005) Incidence and impact of organ dysfunctions associated with sepsis. Chest 127:942–951CrossRefPubMed

Esteban A, Frutos-Vivar F, Ferguson ND, Penuelas O, Lorente JA, Gordo F, Honrubia T, Algora A, Bustos A, Garcia G, Diaz-Reganon IR, de Luna RR (2007) Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Crit Care Med 35:1284–1289CrossRefPubMed

Blanco J, Muriel-Bombin A, Sagredo V, Taboada F, Gandia F, Tamayo L, Collado J, Garcia-Labattut A, Carriedo D, Valledor M, De Frutos M, Lopez MJ, Caballero A, Guerra J, Alvarez B, Mayo A, Villar J (2008) Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit Care 12:R158PubMed

Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34:17–60CrossRefPubMed

Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 30:536–555CrossRefPubMed

Levy MM, Dellinger RP, Townsend SR, Marshall JC, Bion J, Schorr C, Artigas A, Parker MM, Gerlach H, Reinhart K, Silva E, Harvey M, Regan S, Angus DC (2010) The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 36:222–231CrossRefPubMed

Ferrer R, Artigas A, Levy MM, Blanco J, Gonzalez-Diaz G, Garnacho-Montero J, Ibanez J, Palencia E, Quintana M, de la Torre-Prados MV (2008) Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 299:2294–2303CrossRefPubMed

10.

Inigo J, Sendra JM, Diaz R, Bouza C, Sarria-Santamera A (2006) Epidemiology and costs of severe sepsis in Madrid. A hospital discharge study. Med Intensiva 30:197–203CrossRefPubMed

11.

Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303–1310CrossRefPubMed

12.

Levy MM, Fink MP, Marshall JC, Angus DC, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29:530–538PubMed

13.

National Statistics Institute. Mortality tables for the population of Spain. http://www.ine.es/jaxi/menu.do?L=1&type=pcaxis&path=%2Ft20%2Fp319a&file=inebase&L=. Accessed 24 Oct 2008

14.

Quartin AA, Schein RM, Kett DH, Peduzzi PN (1997) Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 277:1058–1063CrossRefPubMed

15.

Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B (2003) Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 31:1–11CrossRefPubMed

16.

Shorr AF, Susla GM, Kollef MH (2004) Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin. Crit Care Med 32:137–143CrossRefPubMed

17.

Talmor D, Greenberg D, Howell MD, Lisbon A, Novack V, Shapiro N (2008) The costs and cost-effectiveness of an integrated sepsis treatment protocol. Crit Care Med 36:1168–1174CrossRefPubMed

18.

Drabinski A, Williams G, Formica C (2001) Observational evaluation of the health state utilities among a cohort of sepsis patients. Value Health 4:128–129CrossRef

19.

Brooks R, Rabin R, de Charro F (2003) The measurement and valuation of health status using EQ-5D: a European perspective. Kluwer Academic, Dordrecht

20.

Instituto Nacional de Salud. Resultados de la gestión analítica en los hospitales del Insalud 2000. http://www.ingesa.msc.es/estadEstudios/documPublica/pdf/gesAnalitica.pdf. Accessed 1 Dec 2008

21.

Vademecum International 2009. Medicom, Barcelona

22.

Van den Berghe G, Wouters PJ, Kesteloot K, Hilleman DE (2006) Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients. Crit Care Med 34:612–616PubMed

23.

Organisation for Economic Co-operation and Development (OECD). OECD statistics on Purchasing Power Parities (PPP). http://www.oecd.org/dataoecd/61/56/39653523.xls. Accessed 15 Dec 2008

24.

Consumer Price Index. National Statistics Institute. http://www.ine.es/en/daco/ipc_en.htm. Accessed 24 Oct 2008

25.

Jegers M, Edbrooke DL, Hibbert CL, Chalfin DB, Burchardi H (2002) Definitions and methods of cost assessment: an intensivist’s guide. ESICM section on health research and outcome working group on cost effectiveness. Intensive Care Med 28:680–685CrossRefPubMed

26.

Efron B, Tibshirani R (1993) An introduction to the Bootstrap. Chapman & Hall/CRC, Boca Raton

27.

Coughlin MT, Angus DC (2003) Economic evaluation of new therapies in critical illness. Crit Care Med 31:S7–S16CrossRefPubMed

28.

Manning WG, Mullahy J (2001) Estimating log models: to transform or not to transform? J Health Econ 20:461–494CrossRefPubMed

29.

Glick HA, Doshi JA, Sonnad SS, Polsky D (2007) Economic evaluation in clinical trials. Oxford University Press, New York

30.

Localio AR, Berlin JA, Ten Have TR, Kimmel SE (2001) Adjustments for center in multicenter studies: an overview. Ann Intern Med 135:112–123PubMed

31.

Sacristan JA, Oliva J, Del Llano J, Prieto L, Pinto JL (2002) What is an efficient health technology in Spain? Gac Sanit 16:334–343PubMed

32.

Karlsson S, Ruokonen E, Varpula T, Ala-Kokko TI, Pettila V (2009) Long-term outcome and quality-adjusted life years after severe sepsis. Crit Care Med 37:1268–1274CrossRefPubMed

33.

Shorr AF, Micek ST, Jackson WL Jr, Kollef MH (2007) Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs? Crit Care Med 35:1257–1262CrossRefPubMed

34.

Sacristan JA, Prieto L, Huete T, Artigas A, Badia X, Chinn C, Hudson P (2004) Cost-effectiveness of drotrecogin alpha (activated) in the treatment of severe sepsis in Spain. Gac Sanit 18:50–57CrossRefPubMed

35.

Talmor D, Shapiro N, Greenberg D, Stone PW, Neumann PJ (2006) When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature. Crit Care Med 34:2738–2747CrossRefPubMed

36.

Suarez D, Haro JM, Novick D, Ochoa S (2008) Marginal structural models might overcome confounding when analyzing multiple treatment effects in observational studies. J Clin Epidemiol 61:525–530CrossRefPubMed

37.

Kahn JM, Bates DW (2008) Improving sepsis care: the road ahead. JAMA 299:2322–2323CrossRefPubMed

Titel: Cost-effectiveness of the Surviving Sepsis Campaign protocol for severe sepsis: a prospective nation-wide study in Spain
verfasst von: David Suarez
Ricard Ferrer
Antonio Artigas
Izaskun Azkarate
José Garnacho-Montero
Gemma Gomà
Mitchell M. Levy
Juan Carlos Ruiz
For the Edusepsis Study Group
Publikationsdatum: 01.03.2011
Verlag: Springer-Verlag
Erschienen in: Intensive Care Medicine / Ausgabe 3/2011
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-010-2102-3

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Cost-effectiveness of the Surviving Sepsis Campaign protocol for severe sepsis: a prospective nation-wide study in Spain

Abstract

Context

Objective

Design

Setting

Patients

Interventions

Main outcome measures

Results

Conclusion

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS

Springer Medizin

Abstract

Context

Objective

Design

Setting

Patients

Interventions

Main outcome measures

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Understanding glycemic control in the critically ill: three domains are better than one

A national survey of Italian physicians’ attitudes towards end-of-life decisions following the death of Eluana Englaro

Severity of the compensatory anti-inflammatory response determined by monocyte HLA-DR expression may assist outcome prediction in cirrhosis

Cerebral gas arterial embolism complicating bronchial biopsies with a flexible bronchoscope: a case report

Prognostic impact of high-flow nasal cannula oxygen supply in an ICU patient with pulmonary fibrosis complicated by acute respiratory failure

Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS